Comparative Pharmacology
Head-to-head clinical analysis: CHLORTHALIDONE versus RESNIBEN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CHLORTHALIDONE versus RESNIBEN.
CHLORTHALIDONE vs RESNIBEN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Thiazide-like diuretic; inhibits sodium-chloride cotransporter in distal convoluted tubule, increasing excretion of sodium, chloride, and water. Also lowers peripheral vascular resistance.
RESNIBEN is a selective inhibitor of the sodium-glucose cotransporter-2 (SGLT2), reducing renal glucose reabsorption and lowering blood glucose levels independently of insulin.
Oral: 25-100 mg once daily; initial dose 25 mg once daily; may increase to 50-100 mg once daily based on response.
1 mg orally once daily, increased to 2 mg once daily based on response and tolerability; maximum 2 mg daily.
None Documented
None Documented
Terminal half-life 40-60 hours (range 35-70h); prolonged in renal impairment
Clinical Note
moderateChlorthalidone + Digoxin
"The risk or severity of adverse effects can be increased when Chlorthalidone is combined with Digoxin."
Clinical Note
moderateChlorthalidone + Digitoxin
"The risk or severity of adverse effects can be increased when Chlorthalidone is combined with Digitoxin."
Clinical Note
moderateChlorthalidone + Deslanoside
"The risk or severity of adverse effects can be increased when Chlorthalidone is combined with Deslanoside."
Clinical Note
moderateTerminal elimination half-life is 6-8 hours in healthy adults, prolonged to 12-15 hours in renal impairment (CrCl <30 mL/min).
Renal: 50-65% unchanged; biliary/fecal: minimal (<5%)
Primarily renal excretion (65-70% as unchanged drug), with biliary/fecal elimination accounting for 20-25% (including metabolites).
Category C
Category C
Thiazide Diuretic
Thiazide Diuretic
Chlorthalidone + Acetyldigitoxin
"The risk or severity of adverse effects can be increased when Chlorthalidone is combined with Acetyldigitoxin."